SHARON COOLEY: Open Payments
NPI 1982669545 · PERU, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$267 in 14 payments from 9 companies in 2025. Trend: 2023 $249 · 2024 $324 · 2025 $267
Food & beverage: $267
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $57 |
| Lilly USA, LLC | 2 | $45 |
| ABBVIE INC. | 2 | $30 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| SANOFI-AVENTIS U.S. LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Abbott Laboratories | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $18 |
Products named: MOUNJARO, Ozempic, TRELEGY ELLIPTA, Wegovy, TZIELD, Korlym, FREESTYLE LIBRE 3, REXULTI.
Industry payments across IN — which companies pay providers there.
